JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

Начало・Списък с акции・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Затворен

18.5 0.87

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

18.19

Максимум

18.62

Ключови измерители
By Trading Economics
Приходи	35M 9.5M
Продажби	35M 94M
Марж на печалбата	10.158
Служители	619
EBITDA	35M 17M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+10.27% upside

Дивиденти
By Dow Jones
Следващи печалби	5.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	279M 2.9B
Предишно отваряне	17.63
Предишно затваряне	18.5

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

8.81 / 10.18 Подкрепа & съпротива

Adaptive Biotechnologies Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.02.2026 г., 23:59 ч. UTC

Пазарно говорене

Oil Prices Fall Amid Signs of U.S.-Iran Negotiations -- Market Talk

1.02.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

1.02.2026 г., 23:44 ч. UTC

Пазарно говорене

Gold Falls as Markets Further Price in Warsh-Led Fed -- Market Talk

1.02.2026 г., 12:47 ч. UTC

Придобивния, сливания и поглъщания

KKR-Led Group Set to Buy Singapore Data-Center Firm Valued at Over $10 Billion -- Update

1.02.2026 г., 03:02 ч. UTC

Придобивния, сливания и поглъщания

KKR-Led Group Set to Buy Singapore Data-Center Firm Valued at Over $10 Billion

1.02.2026 г., 03:01 ч. UTC

Придобивния, сливания и поглъщания

KKR Consortium Currently Owns Near 20% Stake in STT GDC

1.02.2026 г., 03:01 ч. UTC

Придобивния, сливания и поглъщания

KKR Consortium Acquiring Remaining Stake in STT GDC With Singtel, Sources Say

31.01.2026 г., 18:48 ч. UTC

Придобивния, сливания и поглъщания

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- Update

31.01.2026 г., 16:40 ч. UTC

Печалби

'All Boats Are Rising' in Data and Memory, Says Western Digital's CFO. Just Look at the Stocks. -- Barrons.com

31.01.2026 г., 09:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- WSJ

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Nvidia, OpenAI in Talks to Revise Nature of Broader Partnership, Sources Say -- WSJ

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Nvidia CEO Jensen Huang Has Privately Told Colleagues That Deal Is Non-Binding, Sources Say -- WSJ

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Nvidia's Huang Has Privately Criticized OpenAI's Business Strategy, Sources Say -- WSJ

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

OpenAI, Nvidia Deal Talks Stalled in Recent Months, Sources Say -- WSJ

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Nvidia's Huang Expressed Concerns Over Competition OpenAI Faces From Anthropic, Google, Sources Say -- WSJ

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Nvidia Weighing Equity Investment of Tens of Billions of Dollars Into OpenAI, Sources Say -- WSJ

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Negotiations Over $100B OpenAI, Nvidia Deal Stall, Sources Say -- WSJ

30.01.2026 г., 23:41 ч. UTC

Пазарно говорене

Deckers Outdoor Seen as Undervalued -- Market Talk

30.01.2026 г., 23:12 ч. UTC

Придобивния, сливания и поглъщания

Supreme Court of British Columbia Approves Fortescue Purchase of Alta Copper

30.01.2026 г., 22:20 ч. UTC

Печалби

Verizon Posts Strong Subscriber Gains Under New CEO -- WSJ

30.01.2026 г., 22:10 ч. UTC

Пазарно говорене

Disney CEO's Exit Plan Marks Abrupt End to Messy Succession -- Market Talk

30.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

30.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

30.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

30.01.2026 г., 21:42 ч. UTC

Печалби

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30.01.2026 г., 21:36 ч. UTC

Печалби

GE Aerospace and GE Vernova Issue Their Annual Reports. They Contain Messages for Investors. -- Barrons.com

30.01.2026 г., 21:33 ч. UTC

Печалби

Tesla Stock Rebounds From Earnings Dip. SpaceX Is Helping. -- Barrons.com

30.01.2026 г., 20:42 ч. UTC

Печалби

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30.01.2026 г., 20:37 ч. UTC

Придобивния, сливания и поглъщания

Why a Ruling Over CK Hutchison's Panama Canal Ports Matters -- and What's Next -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Adaptive Biotechnologies Corp Прогноза

Ценова цел

By TipRanks

10.27% нагоре

12-месечна прогноза

Среден 20.4 USD 10.27%

Висок 21 USD

Нисък 20 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Adaptive Biotechnologies Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Adaptive Biotechnologies Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.81 / 10.18Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.